Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ziga Rotar

Showing results (21-30 of 63) with videos related to

Pageof 7
Sort By:
Joint Bone Spine|December 2, 2023
Oral glucocorticoid use in patients with rheumatoid arthritis initiating TNF-inhibitors, tocilizumab or abatacept: Results from the international TOCERRA and PANABA observational collaborative studiesKim Lauper, Denis Mongin, Sytske Anne Bergstra, et al.
Annals of the Rheumatic Diseases|September 13, 2022
After JAK inhibitor failure: to cycle or to switch, that is the question - data from the JAK-pot collaboration of registriesManuel Pombo-Suarez, Carlos Sanchez-Piedra, Juan Gómez-Reino, et al.
RMD Open|November 3, 2024
Impact of patient characteristics on ASDAS disease activity state cut-offs in axial spondyloarthritis: results from nine European rheumatology registriesLykke M Ørnbjerg, Stylianos Georgiadis, Tore K Kvien, et al.
Arthritis Research & Therapy|September 30, 2025
Sacroiliac joint involvement in psoriatic arthritis - MRI, radiographic and clinical findings in 581 European routine care patientsNora Vladimirova, Anna Ef Hadsbjerg, Simon Krabbe, et al.
Rheumatology (Oxford, England)|August 19, 2020
The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registriesDelphine S Courvoisier, Katarina Chatzidionysiou, Denis Mongin, et al.
BMC Rheumatology|July 11, 2025
The relationship between lifestyle factors and outcome of treatment with TNFα inhibitors in axial spondyloarthritis - results from 14 European countriesGareth T Jones, Ovidiu Rotariu, Ross MacDonald, et al.
RMD Open|December 17, 2025
Discrepancies between routine sacroiliac joint MRI reporting and current expert recommendations in patients with spondyloarthritisAnna E F Hadsbjerg, Simon Krabbe, Nora Vladimirova, et al.
Rheumatology (Oxford, England)|September 22, 2023
Second and third TNF inhibitors in European patients with axial spondyloarthritis: effectiveness and impact of the reason for switchingLouise Linde, Lykke Midtbøll Ørnbjerg, Cecilie Heegaard Brahe, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 15, 2025
Incidence of Major Adverse Cardiovascular Events in Patients With Rheumatoid Arthritis Treated With JAK Inhibitors Compared With Biologic Disease-Modifying Antirheumatic Drugs: Data From an International Collaboration of RegistriesRomain Aymon, Denis Mongin, Romain Guemara, et al.
Annals of the Rheumatic Diseases|December 10, 2023
Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the 'JAK-pot' study)Romain Aymon, Denis Mongin, Sytske Anne Bergstra, et al.
Pageof 7

Showing results (21-30 of 63) with videos related to

Sort By:
Pageof 7
Joint Bone Spine|December 2, 2023
Oral glucocorticoid use in patients with rheumatoid arthritis initiating TNF-inhibitors, tocilizumab or abatacept: Results from the international TOCERRA and PANABA observational collaborative studiesKim Lauper, Denis Mongin, Sytske Anne Bergstra, et al.
Annals of the Rheumatic Diseases|September 13, 2022
After JAK inhibitor failure: to cycle or to switch, that is the question - data from the JAK-pot collaboration of registriesManuel Pombo-Suarez, Carlos Sanchez-Piedra, Juan Gómez-Reino, et al.
RMD Open|November 3, 2024
Impact of patient characteristics on ASDAS disease activity state cut-offs in axial spondyloarthritis: results from nine European rheumatology registriesLykke M Ørnbjerg, Stylianos Georgiadis, Tore K Kvien, et al.
Arthritis Research & Therapy|September 30, 2025
Sacroiliac joint involvement in psoriatic arthritis - MRI, radiographic and clinical findings in 581 European routine care patientsNora Vladimirova, Anna Ef Hadsbjerg, Simon Krabbe, et al.
Rheumatology (Oxford, England)|August 19, 2020
The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registriesDelphine S Courvoisier, Katarina Chatzidionysiou, Denis Mongin, et al.
BMC Rheumatology|July 11, 2025
The relationship between lifestyle factors and outcome of treatment with TNFα inhibitors in axial spondyloarthritis - results from 14 European countriesGareth T Jones, Ovidiu Rotariu, Ross MacDonald, et al.
RMD Open|December 17, 2025
Discrepancies between routine sacroiliac joint MRI reporting and current expert recommendations in patients with spondyloarthritisAnna E F Hadsbjerg, Simon Krabbe, Nora Vladimirova, et al.
Rheumatology (Oxford, England)|September 22, 2023
Second and third TNF inhibitors in European patients with axial spondyloarthritis: effectiveness and impact of the reason for switchingLouise Linde, Lykke Midtbøll Ørnbjerg, Cecilie Heegaard Brahe, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 15, 2025
Incidence of Major Adverse Cardiovascular Events in Patients With Rheumatoid Arthritis Treated With JAK Inhibitors Compared With Biologic Disease-Modifying Antirheumatic Drugs: Data From an International Collaboration of RegistriesRomain Aymon, Denis Mongin, Romain Guemara, et al.
Annals of the Rheumatic Diseases|December 10, 2023
Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the 'JAK-pot' study)Romain Aymon, Denis Mongin, Sytske Anne Bergstra, et al.
Pageof 7